ArticleFrontiers in immunology2026

Immunotherapy plus chemotherapy improves survival in SMARCA4-deficient NSCLC: a real-world cohort study.

YuJun He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.